Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

MD Clinical

Neither a doctor nor a teaching hospital

Research payments

$3,986,152

282 payments

Through program year 2024, MD Clinical is reported as receiving $3,986,152 in research payments, across 282 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $201 1
2023 Research $23,905 5
2022 Research $57,175 10
2021 Research $2,085,761 56
2020 Research $735,676 119
2019 Research $1,083,434 91

Breakdown

Who paid Research payments · program years 2019–2024
  1. Merck Sharp & Dohme Corporation $2,898,309 58 payments
  2. Allergan Inc. $716,930 125 payments
  3. Genentech, Inc. $91,964 15 payments
  4. Acorda Therapeutics, Inc $88,274 8 payments
  5. Pfizer Inc. $74,815 9 payments
  6. Eisai Inc. $39,387 11 payments
  7. H. Lundbeck A S $24,000 2 payments
  8. Valneva Austria GmbH $23,855 4 payments
  9. Eli Lilly and Company $21,631 11 payments
  10. Novo Nordisk AS $5,693 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Randomized, Double Blind, Placebo-Controlled Investigation of the Safety, Tolerability, and Pharmacokinetics of Multiple-Dose Regimens of MK-1942 $1,718,663 5 payments
  2. A Randomized Double Blind Clinical Trial to Evaluate the Effects of MK-7264 in Participants with Obstructive Sleep Apnea $880,391 35 payments
  3. A Clinical Study to Evaluate a Cognitive Platform to Support Development of Symptomatic Therapies in Participants at Risk for Alzheimer s Disease $241,384 4 payments
  4. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $171,250 21 payments
  5. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $164,090 25 payments
  6. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $155,225 24 payments
  7. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $125,981 16 payments
  8. A Phase Ib Randomized Blinded Placebo Controlled Multiple Ascending Dose Study With Bfkb8488a $91,964 15 payments
  9. A Phase 2A Randomized Doubleblind Placebocontrolled 3Arm Parallel Group Study to Evaluate Safety Tolerability and Pharmacodynamics of Pf06835919 Administered Daily for 16 Weeks in Adults With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus on Metformin $64,753 6 payments
  10. Pharmacokinetic Study of CVT-301 Levodopa Inhalation Powder $51,665 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record